Shares of NeoGenomics (NASDAQ: NEO) jumped 53.9% this week, according to data from S&P Global Market Intelligence. The cancer diagnostic company's stock closed last Friday at $7.31 a share and then ...
Hosted on MSN
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
NeoGenomics stock jumped Wednesday after the company issued a strong 2025 outlook. That partially reversed a shocking sell-off after Chief Executive Chris Smith announced his retirement on Monday.
NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...
On Thursday, Benchmark analyst maintained a Hold rating on shares of Neogenomics (NASDAQ: NEO). The analysis comes ahead of the company's investor conference presentation scheduled for the same day.
NeoGenomics sees more growth ahead. After announcing a new CEO last week, the local company has provided its financial outlook for this year – and beyond. The Fort Myers-based cancer testing and ...
NeoGenomics (NEO) is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat ...
The company has a new CEO, Chris Smith, who took over in July. NeoGenomics reported a 6% rise in revenue year over year. The company seems to be benefitting from a post-pandemic environment. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback